Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-036762
Filing Date
2024-08-12
Accepted
2024-08-12 16:08:30
Documents
72
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q espr-20240630.htm   iXBRL 10-Q 1097193
2 EX-10.1 exhibit101royaltysaleagree.htm EX-10.1 361185
3 EX-31.1 espr-ex311x06302024.htm EX-31.1 10924
4 EX-31.2 espr-ex312x06302024.htm EX-31.2 10993
5 EX-32.1 espr-ex321x06302024.htm EX-32.1 8279
  Complete submission text file 0001628280-24-036762.txt   7002473

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20240630.xsd EX-101.SCH 64025
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT espr-20240630_cal.xml EX-101.CAL 52610
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT espr-20240630_def.xml EX-101.DEF 304502
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20240630_lab.xml EX-101.LAB 625199
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20240630_pre.xml EX-101.PRE 460058
75 EXTRACTED XBRL INSTANCE DOCUMENT espr-20240630_htm.xml XML 759970
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35986 | Film No.: 241196823
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)